DGAP-News: Peter Osborne Joins myoscience as Chief Financial Officer
(firmenpresse) - myoscience
16.09.2013 13:00
---------------------------------------------------------------------------
REDWOOD CITY, Calif., 2013-09-16 13:00 CEST (GLOBE NEWSWIRE) --
myoscience, inc. is pleased to announce the addition of Peter Osborne to the
team as chief financial officer (CFO). Osborne has over 25 years of experience
in high growth public and private companies, most notably with Hansen Medical
and VNUS Medical Technologies, and most recently with SentreHEART, Inc.
'Peter has extensive experience in scaling the business, executing global
strategy and implementing financial controls to position myoscience for
continued success,' said Clint Carnell, CEO of myoscience. 'His leadership will
help myoscience expand globally and with additional clinical indications.'
Osborne led VNUS through dramatic revenue growth expanding to more than 350
employees and selling into more than 40 countries, culminating in its
acquisition by Covidien in 2009. 'It is exciting to be joining myoscience at
this inflection point in their growth. The positive clinical benefits of
Focused Cold Therapy(TM) experienced by patients and physicians is accelerating
market adoption,' said Osborne. 'The current strategic needs of the company and
my experience in fully realizing the value of innovative technologies fit
perfectly to guiding the business to its next stage of commercial success.'
About myoscience
Silicon Valley, California-based myoscience is a privately-held medical device
company committed to making its platform technology, Focused Cold Therapy(TM),
the standard of care for the treatment of peripheral nerve conditions. Focused
Cold Therapy is currently approved in Europe and Canada for temporary wrinkle
reduction, temporary pain reduction and treatment of dermatologic conditions.
The myoscience technology has also been cleared in the United States for use in
pain management and general surgical use. For more information, please visit
www.myoscience.com.
The myoscience logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=13581
CONTACT: Alexandra Mack, myoscience inc.
Tel: 00 1 650 421 0609
amack(at)myoscience.com
News Source: NASDAQ OMX
16.09.2013 Dissemination of a Corporate News, transmitted by DGAP -
a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: myoscience
United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US9902131674
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 16.09.2013 - 13:00 Uhr
Sprache: Deutsch
News-ID 296783
Anzahl Zeichen: 5876
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 325 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Peter Osborne Joins myoscience as Chief Financial Officer"
steht unter der journalistisch-redaktionellen Verantwortung von
myoscience (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
